A pharmaceutical composition comprising a compound selected from Formula I: tautomers, resolved enantiomers, resolved diastereomers, solvates, and salts thereof; and a second drug; wherein in Formula I: R 1 is H, Me, Et, vinyl, CF 3, CHF 2 or CH 2 F; R 2 is H; R 5 is H, Me, Et, or CF 3; A is G is phenyl optionally substituted by one to four R 9 groups or a 5-6 membered heteroaryl optionally substituted by a halogen; R 6 and R 7 are independently H, OCH 3, (C 3 -C 6 cycloalkyl)-(CH 2), (C 3 -C 6 cycloalkyl)-(CH 2 CH 2), V-(CH 2) 0-1 wherein V is a 5-6 membered heteroaryl, W-(CH 2) 1-2 wherein W is phenyl optionally substituted with F, Cl, Br, I, OMe, CF 3 or Me, C 3 -C 6 -cycloalkyl optionally substituted with C 1 -C 3 alkyl or O(C 1 -C 3 alkyl), hydroxy-(C 3 -C 6 -cycloalkyl), fluoro-(C 3 -C 6 -cycloalkyl), CH(CH 3)CH phenyl, 4-6 membered heterocycle optionally substituted with F, OH, C 1 -C 3 alkyl, cyclopropylmethyl or C(=O)(C 1 -C 3 alkyl), or C 1 -C 6 -alkyl optionally substituted with one or more groups independently selected from OH, oxo, O(C 1 -C 6 -alkyl), CN, F, NH 2, NH(C 1 -C 6 -alkyl), N(C 1 -C 6 -alkyl) 2, cyclopropyl, phenyl, imidazolyl, piperidinyl, pyrrolidinyl, morpholinyl, tetrahydrofuranyl, oxetanyl or tetrahydropyranyl, or R 6 and R 7 together with the nitrogen to which they are attached form a 4-7 membered heterocyclic ring optionally substituted with one or more groups independently selected from OH, halogen, oxo, CF 3, CH 2 CF 3, CH 2 CH 2 OH, O(C 1 -C 3 alkyl), C(=O)CH 3, NH 2, NHMe, N(Me) 2, S 2 CH 3, cyclopropylmethyl and C 1 -C 3 alkyl; R 3 and R b are H, or R a is H, and R b and R 6 together with the atoms to which they are attached form a 5-6 membered heterocyclic ring having one or two ring nitrogen atoms; R c and R d are H or Me, or R c and R d together with the atom to which they are attached from a cyclopropyl ring; R 8 is H, Me, F or OH, or R 8 and R 6 together with the atoms to which they are attached form a 5-6 membered heterocyclic ring having one or two ring nitrogen atoms; each R 9 is independently halogen, C 1 -C 6 -alkyl, C 3 -C 6 -cycloalkyl, O-(C 1 -C 6 -alkyl), CF 3, OCF 3, S(C 1 -C 6 -alkyl), CN, OCH 2 -phenyl, CH 2 O-phenyl, NH 2, NH-(C 1 -C 6 -alkyl), N-(C 1 -C 6 -alkyl) 2, piperidine, pyrrolidine, CH 2 F, CHF 2, OCH 2 F, OCHF 2, OH, SO 2 (C 1 -C 6 -alkyl), C NH 2, C NH(C 1 -C 6 -alkyl), and C N(C 1 -C 6 -alkyl) 2; R 10 is H or Me; and m, n and p are independently 0 or 1. R 1 is H, Me, Et, vinyl, CF 3, CHF 2 or CH 2 F; R 2 is H; R 5 is H, Me, Et, or CF 3; A is G is phenyl optionally substituted by one to four R 9 groups or a 5-6 membered heteroaryl optionally substituted by a halogen; R 6 and R 7 are independently H, OCH 3, (C 3 -C 6 cycloalkyl)-(CH 2), (C 3 -C 6 cycloalkyl)-(CH 2 CH 2), V-(CH 2) 0-1 wherein V is a 5-6 membered heteroaryl, W-(CH 2) 1-2 wherein W is phenyl optionally substituted with F, Cl, Br, I, OMe, CF 3 or Me, C 3 -C 6 -cycloalkyl optionally substituted with C 1 -C 3 alkyl or O(C 1 -C 3 alkyl), hydroxy-(C 3 -C 6 -cycloalkyl), fluoro-(C 3 -C 6 -cycloalkyl), CH(CH 3)CH phenyl, 4-6 membered heterocycle optionally substituted with F, OH, C 1 -C 3 alkyl, cyclopropylmethyl or C(=O)(C 1 -C 3 alkyl), or C 1 -C 6 -alkyl optionally substituted with one or more groups independently selected from OH, oxo, O(C 1 -C 6 -alkyl), CN, F, NH 2, NH(C 1 -C 6 -alkyl), N(C 1 -C 6 -alkyl) 2, cyclopropyl, phenyl, imidazolyl, piperidinyl, pyrrolidinyl, morpholinyl, tetrahydrofuranyl, oxetanyl or tetrahydropyranyl, or R 6 and R 7 together with the nitrogen to which they are attached form a 4-7 membered heterocyclic ring optionally substituted with one or more groups independently selected from OH, halogen, oxo, CF 3, CH 2 CF 3, CH 2 CH 2 OH, O(C 1 -C 3 alkyl), C(=O)CH 3, NH 2, NHMe, N(Me) 2, S 2 CH 3, cyclopropylmethyl and C 1 -C 3 alkyl; R 3 and R b are H, or R a is H, and R b and R 6 together with the atoms to which they are attached form a 5-6 membered heterocyclic ring having one or two ring nitrogen atoms; R c and R d are H or Me, or R c and R d together with the atom to which they are attached from a cyclopropyl ring; R 8 is H, Me, F or OH, or R 8 and R 6 together with the atoms to which they are attached form a 5-6 membered heterocyclic ring having one or two ring nitrogen atoms; each R 9 is independently halogen, C 1 -C 6 -alkyl, C 3 -C 6 -cycloalkyl, O-(C 1 -C 6 -alkyl), CF 3, OCF 3, S(C 1 -C 6 -alkyl), CN, OCH 2 -phenyl, CH 2 O-phenyl, NH 2, NH-(C 1 -C 6 -alkyl), N-(C 1 -C 6 -alkyl) 2, piperidine, pyrrolidine, CH 2 F, CHF 2, OCH 2 F, OCHF 2, OH, SO 2 (C 1 -C 6 -alkyl), C NH 2, C NH(C 1 -C 6 -alkyl), and C N(C 1 -C 6 -alkyl) 2; R 10 is H or Me; and m, n and p are independently 0 or 1.